NewTimesSpace (newtimespace.com) reports: Keytop Parking (2272.HK) launched its subscription on June 17, offering approximately 10.11 million H shares globally at HK$39.55 per share. The entry fee for one board lot of 60 shares is approximately HK$2,397. The listing is expected on June 26, with CICC and CMBC Capital serving as joint sponsors.
New Times Space (newtimespace.com) reports: Lingyi iTech (1688.HK) launched its subscription on June 17, offering approximately 811.81 million H shares globally at a maximum price of HK$10.18 per share. The entry fee for one board lot of 660 shares is approximately HK$6,787. The listing is expected on June 26, with Guotai Haitong and Guotai Junan International serving as exclusive sponsors.
NewTimesSpace (newtimespace.com) reports: CFMEE (9630.HK) launched its subscription on June 17, offering approximately 12.84 million H shares globally at a maximum price of HK$252.73 per share. The entry fee for one board lot of 50 shares is approximately HK$12,764. The listing is expected on June 26, with CICC serving as the exclusive sponsor.
NewTimeSpace News: Hengrui Medicine announced on June 16 that SHR-6914 Injection developed by its subsidiary Suzhou Shengdiya Biomedicine Co., Ltd. has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving clinical trials for its monotherapy in the treatment of prostate cancer.
NewTimeSpace News: Regent Pacific Group announced in an announcement dated June 16 that the New Drug Application for its proprietary Senstend™ has been approved by the National Medical Products Administration, with a four-year data protection period attached.
NewTimeSpace News: CSPC Pharmaceutical Group announced on June 16 that the New Drug Application (NDA) for its self-developed Valsartan Levoamlodipine Maleate Tablets (Tablet SYH9056) has been accepted by the National Medical Products Administration.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the Phase 2 clinical trial of HLX43 for Injection, a PD-L1-targeted antibody-drug conjugate (ADC), in combination with Hansizhu® (serplulimab injection) for neoadjuvant therapy of non-small cell lung cancer (NSCLC), has obtained approval from the relevant Human Research Ethics Committee (HREC) of Australia and completed Clinical Trial Notification (CTN) filing with the Therapeutic Goods Administration (TGA). Previously, key subgroup data of HLX43 in NSCLC were presented as a rapid oral abstract at the 2026 ASCO Annual Meeting.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the global multicenter Phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for the treatment of wet age-related macular degeneration (wAMD), has reached its primary endpoint. The trial results demonstrated that the mean change in best corrected visual acuity (BCVA) from baseline at Week 36 and Week 48 in the HLX04-O group was non-inferior to that of the ranibizumab group, with a favorable safety profile.
NewTimeSpace News: On June 16, 2026, RoboSense(02498.HK) remained weak in afternoon trading. As of 15:30, its intraday price stood at HK$25.96, down 7.55%. The Peacock chip will officially launch mass production within 2026.
NewTimeSpace (newtimespace.com) News: On June 16, 2026, the share price of Xiaomi-W (01810.HK) continued to fluctuate and weaken. As of 1:29 PM, the company was quoted at HK$25.780, down 1.83%.
NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) announced that the marketing application for Piracetam Injection developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has been approved by the National Medical Products Administration (NMPA). The product is indicated for memory impairment and mild to moderate cerebral dysfunction caused by acute and chronic cerebrovascular diseases, brain trauma and toxic encephalopathy, and also for mental retardation in children. Piracetam Injection is a Class B drug covered by the National Medical Insurance Catalogue, with domestic sales exceeding RMB250 million in 2025.
NewTimeSpace (newtimespace.com) News, On June 16, 2026, large model concept stocks such as Zhipu (2513.HK) and Mininglamp Technology (2718.HK) strengthened during morning trading. As of 10:08 AM, Mininglamp Technology (2718.HK) was quoted at HK$247.600, up 2.91%. Choice data shows that Mininglamp Technology's share price has recently delivered a strong rally, with its cumulative gain over the past five days exceeding 35% as of now.
NewTimeSpace News: CSPC Pharmaceutical Group announced on June 15 that its self-developed Albumin-bound Paclitaxel for Injection (II) has been approved for launch by the National Medical Products Administration.
On June 15, Hong Kong stocks fluctuated higher as the AI and semiconductor supply chains erupted across the board. ZHIPU AI skyrocketed over 32% following the full release and imminent open-sourcing of its GLM-5.2 model, driving a market revaluation of domestic LLMs, while semiconductor and AI hardware equities like Hua Hong and Lenovo surged. Industry dynamics highlighted a stark divergence: the US Commerce Department imposed strict export controls on Anthropic's latest models, forcing a global access suspension, whereas ZHIPU AI championed accessibility by fully opening its most powerful model. Concurrently, XUNCE forged strategic alliances with three major domestic GPU manufacturers to develop integrated hardware-software solutions tailored for vertical industries.
NewTimeSpace News: On June 15, 2026, XPENG-W(09868.HK) trended lower amid afternoon volatility. As of 15:23, the stock was quoted at HK$55.75, down 3.38%. Its first mass-produced Robotaxi rolled off the production line in Guangzhou on May 18, 2026, with demonstration operations expected to launch in the second half of 2026.
NewTimeSpace (newtimespace.com) News: On June 15, 2026, the semiconductor concept sector in the Hong Kong stock market continued to strengthen, with the share price of ASMPT (00522.HK) pulling up substantially. As of 1:44 PM, the company's share price was quoted at HK$199.300, up 8.97%.
